Venetoclax and Ibrutinib in Treating Patients With High-Risk Chronic Lymphocytic Leukemia

  • End date
    Jun 1, 2025
  • participants needed
  • sponsor
    M.D. Anderson Cancer Center
Updated on 29 May 2022
platelet count
lymphoid leukemia
chronic lymphocytic leukemia
flow cytometry
residual tumor
neutrophil count
beta human chorionic gonadotrophin


This phase II trial studies how well venetoclax and ibrutinib work in treating patients with high-risk chronic lymphocytic leukemia. Drugs used in chemotherapy, such as venetoclax, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving venetoclax and ibrutinib may work better in treating patients with chronic lymphocytic leukemia.



I. To estimate the therapeutic efficacy of venetoclax consolidation in patients who have detectable chronic lymphocytic leukemia (CLL) after receiving ibrutinib monotherapy for at least 12 months and who have high risk CLL.


I. Determine complete remission (CR)/complete remission with incomplete hematologic recovery (CRi) rate after 6, 12, 18 and 24 cycles of combination therapy in patients who were not in CR/Cri at study initiation and estimate the time to best response with this combination.

II. Determine the cumulative rate of bone marrow minimal residual disease (MRD)-free complete responders by an assay method with at least 0.01% sensitivity and median time to MRD-negativity.

III. Determine the safety of combined ibrutinib and venetoclax. IV. Determine the progression-free and overall survival.

OUTLINE: This is a dose-escalation study of venetoclax.

Patients receive venetoclax orally (PO) once daily (QD) and ibrutinib PO QD. Treatment repeat every 4 weeks for up to 24 cycles in the absence of disease progression or unaccepted toxicity.

After completion of study treatment, patients are followed up every 6-12 months.

Condition Chronic Lymphocytic Leukemia
Treatment Ibrutinib, venetoclax, Allopurinol
Clinical Study IdentifierNCT03128879
SponsorM.D. Anderson Cancer Center
Last Modified on29 May 2022


Yes No Not Sure

Inclusion Criteria

• Patients must have a diagnosis of CLL/CLL and have high-risk cytogenetic features or molecular features, defined as: del(17p), mutated TP53, Note: some patients treated with ibrutinib may no longer have detectable fluorescence in situ hybridization (FISH), karyotypic or molecular abnormalities after 12 months of therapy. These patients will be eligible if they fulfill the above criteria on a bone marrow biopsy or peripheral blood specimen taken either prior to starting ibrutinib, provided they did not receive treatment for their CLL between the date of the lab test and starting ibrutinib or at some time during their ibrutinib therapy and analyzed at a Clinical Laboratory Improvement Act (CLIA)-accredited laboratory
Patients must have received at least 12 months of ibrutinib therapy and have measurable CLL by at least one of the following
Absolute monoclonal lymphocyte count > 4000/microL; OR
Measurable lymph nodes with at least one node > 1.5 cm in diameter on computed tomography (CT); OR
Eastern Cooperative Oncology Group (ECOG) performance status =< 2
Bone marrow with >= 30% lymphocytes on aspirate differential OR
Detectable CLL cells using a standardized flow cytometry assay for minimal residual disease
Serum bilirubin =< 1.5 x upper limit of normal (ULN) or =< 3 x ULN for patients with Gilbert's disease
Serum creatinine clearance of >= 50 ml/min (calculated or measured)
Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3.0 x ULN, unless clearly due to disease involvement
Platelet count of greater than 50,000/ul, with no platelet transfusion in prior 2 weeks
International normalized ratio (INR) < 1.5
Absolute neutrophil count (ANC) >= 1000/ul in the absence of growth factor support unless due to compromised bone marrow production from CLL, indicated by >= 80% CLL in marrow
Absence of uncontrolled cardiac arrhythmia
Hemoglobin >= 8 mg/dL
Echocardiogram demonstrating left ventricular ejection fraction (LVEF) >= 35%
New York Heart Association (NYHA) functional class =< 2
Ability to provide informed consent and adhere to the required follow-up
Women of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-human chorionic gonadotropin [hCG]) pregnancy test result within 7 days prior to the first dose of study drugs and must agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) and a barrier method (e.g., condoms, vaginal ring, sponge, etc.) during the period of therapy and for 30 days after the last dose of study drug. Women of nonchildbearing potential are those who are postmenopausal (defined as absence of menses for >= 1 year) or who have had a bilateral tubal ligation or hysterectomy. Men who have partners of childbearing potential must agree to use effective contraception, defined above, during the study and for 30 days following the last dose of study drug
Complete abstinence is a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study treatments. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject
Patients or their legally authorized representative must provide written informed

Exclusion Criteria

Richter transformation
Active malignancy requiring systemic therapy, other than CLL, with the exception of: adequately treated in situ carcinoma of the cervix uteri; adequately treated basal cell carcinoma or localized squamous cell carcinoma of the skin; previous malignancy confined and surgically resected (or treated with other modalities) with curative intent
Major surgery, radiotherapy, chemotherapy, biologic therapy, immunotherapy, experimental therapy within 3 weeks prior to the first dose of the study drug
Grade 3 or 4 hemorrhage within the past 3 weeks
Uncontrolled active infections (viral, bacterial, and fungal)
Females who are pregnant or lactating
Known positive serology for human immunodeficiency virus (HIV)
Active hepatitis C, defined by the detection of hepatitis C ribonucleic acid (RNA) in plasma by polymerase chain reaction (PCR)
Active, uncontrolled autoimmune phenomenon (autoimmune hemolytic anemia or immune thrombocytopenia) requiring steroid therapy > 20 mg prednisone daily or equivalent, within 7 days of starting venetoclax
Received other investigational therapeutic agent for CLL/SLL within 21 days of starting venetoclax
Concurrent use of warfarin
Active hepatitis B infection (defined as the presence of detectable hepatitis B virus [HBV] deoxyribonucleic acid [DNA] or hemoglobin E [HBe] antigen). Patients who are hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive are eligible, provided HBV DNA is negative. These patients will have monthly monitoring of HBV DNA for the duration of the study, if clinically indicated. Please note that patients who have received intravenous immunoglobulin (IVIG) may have false positive HBcAb results. In such patients, if HBV DNA and HBsAg are negative, serial HBV DNA monitoring is not necessary
Received strong CYP3A inhibitors or strong CYP3A inducers within 7 days of starting venetoclax
Consuming grapefruit, grapefruit products, Seville oranges, or star fruit within 7 days of starting venetoclax
Prior treatment with venetoclax or other Bcl-2 inhibitor
Malabsorption syndrome or other condition that precludes enteral route of administration
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note